Table 3—

Crude and standardized prevalence of IFG in adults age ≥20 years in the U.S. population, 1999–2002

Age (years)
≥2020–3940–59≥60≥65≥20, standardized*
Total population26.0 (23.7–28.5)15.9 (13.4–18.8)29.9 (26.6–33.4)37.5 (34.2–40.9)39.1 (35.5–42.9)26.0 (23.8–28.4)
    Men32.6 (29.4–36.1)23.9 (19.5–28.8)37.2 (32.6–42.1)41.8 (36.2–47.6)43.2 (37.2–49.4)32.8 (29.8–36.0)
    Women20.0 (17.9–22.2)8.2 (6.0–11.1)22.9 (19.8–26.3)34.2 (30.2–38.5)36.0 (32.0–40.2)19.5 (17.5–21.7)
Non-Hispanic whites27.0 (24.1–30.2)15.3 (11.9–19.3)30.2 (25.8–35.1)38.8 (34.4–42.3)40.0 (36.2–43.9)26.1 (23.4–29.1)
    Men33.7 (29.6–38.0)22.6 (16.9–29.5)37.8 (31.7–44.3)44.1 (37.7–50.7)45.0 (38.5–51.7)33.1 (29.3–37.1)
    Women20.9 (18.3–23.8)8.2 (5.2–12.7)22.8 (18.5–27.8)34.7 (30.0–39.6)36.2 (31.8–40.9)19.6 (17.1–22.4)
Non-Hispanic blacks16.8 (13.9–20.1)9.5 (5.9–15.0)21.3 (15.8–28.2)25.5 (20.0–31.9)24.5 (17.9–32.5)17.7 (14.8–21.0)
    Men19.2 (15.3–23.8)10.9 (6.1–18.6)26.9 (19.7–35.5)23.9 (15.0–35.8)23.0 (13.6–36.2)19.7 (15.9–24.2)
    Women14.9 (11.3–19.3)8.4 (4.5–15.3)16.7 (10.2–26.2)26.6 (19.7–34.7)25.6 (18.8–33.8)15.6 (11.9–20.2)
Mexican Americans30.1 (26.7–33.8)25.2 (20.5–30.6)40.1 (35.4–44.9)32.1 (27.1–37.6)34.3 (27.8–41.6)31.6 (28.8–34.5)
    Men41.1 (37.6–44.7)36.5 (31.5–41.9)53.5 (46.7–60.1)34.3 (28.3–40.8)31.9 (24.4–40.6)42.2 (39.0–45.5)
    Women18.0 (14.0–23.0)12.0 (7.2–19.1)25.7 (20.3–32.1)30.4 (22.2–40.0)36.1 (25.3–48.5)21.2 (17.4–25.5)
  • Data are % (95% CI). IFG is defined as fasting plasma glucose 5.6–7.0 mmol/l. Values for the total population and for men and women include those of race/ethnic groups not listed separately. All CIs were logit transformed.

  • *

    * Standardized to the 2000 U.S. Census population by age and sex for the total population and race/ethnic groups and by age for sex-groups.